American Century Companies Inc. Makes New Investment in IDEAYA Biosciences, Inc. $IDYA

American Century Companies Inc. bought a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 11,908 shares of the company's stock, valued at approximately $195,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of IDEAYA Biosciences by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 7,483 shares of the company's stock valued at $123,000 after purchasing an additional 627 shares during the period. Swiss National Bank grew its position in shares of IDEAYA Biosciences by 0.8% in the first quarter. Swiss National Bank now owns 150,800 shares of the company's stock valued at $2,470,000 after purchasing an additional 1,200 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of IDEAYA Biosciences by 6.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,301 shares of the company's stock valued at $349,000 after purchasing an additional 1,214 shares during the period. PNC Financial Services Group Inc. grew its position in shares of IDEAYA Biosciences by 180.2% in the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock valued at $39,000 after purchasing an additional 1,546 shares during the period. Finally, CWM LLC grew its position in shares of IDEAYA Biosciences by 325.7% in the first quarter. CWM LLC now owns 2,371 shares of the company's stock valued at $39,000 after purchasing an additional 1,814 shares during the period. Hedge funds and other institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Stock Up 0.4%

NASDAQ:IDYA traded up $0.11 on Thursday, hitting $24.82. The stock had a trading volume of 1,009,689 shares, compared to its average volume of 1,156,945. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of -6.55 and a beta of 0.12. The company has a fifty day moving average price of $23.84 and a two-hundred day moving average price of $20.70. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $37.80.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The firm had revenue of $6.00 million for the quarter, compared to analysts' expectations of $3.48 million. During the same quarter in the prior year, the company posted ($0.68) EPS. The business's revenue was up NaN% on a year-over-year basis. As a group, analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on IDYA shares. Royal Bank Of Canada lifted their target price on shares of IDEAYA Biosciences from $36.00 to $38.00 and gave the company an "outperform" rating in a research report on Tuesday. Cantor Fitzgerald restated an "overweight" rating on shares of IDEAYA Biosciences in a research report on Tuesday. Wells Fargo & Company started coverage on shares of IDEAYA Biosciences in a research report on Thursday, June 26th. They set an "overweight" rating and a $44.00 price target on the stock. Stephens restated an "overweight" rating and set a $45.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday. Finally, Citigroup restated a "buy" rating on shares of IDEAYA Biosciences in a research report on Tuesday. Twelve investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $42.75.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.